FLUDARA POWDER FOR SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

FLUDARABINE PHOSPHATE (FLUDARABINE PHOSPHATE SODIUM)

Предлага се от:

SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC

АТС код:

L01BB05

INN (Международно Name):

FLUDARABINE

дозиране:

50MG

Лекарствена форма:

POWDER FOR SOLUTION

Композиция:

FLUDARABINE PHOSPHATE (FLUDARABINE PHOSPHATE SODIUM) 50MG

Начин на приложение:

INTRAVENOUS

Броя в опаковка:

2ML

Вид предписание :

Prescription

Терапевтична област:

ANTINEOPLASTIC AGENTS

Каталог на резюме:

Active ingredient group (AIG) number: 0123842001; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2011-03-31

Данни за продукта

_ _
_ _
_Page 1 of 49 _
PRODUCT MONOGRAPH
PR
FLUDARA
®
fludarabine phosphate for injection
50 mg per vial as sodium salt
and
fludarabine phosphate tablets
10 mg
Antineoplastic
Genzyme Canada Inc.
800-2700 Matheson Blvd. East, West Tower
Mississauga, ON
L4W 4V9
Canada
www.genzyme.ca
DATE OF REVISION:
April 19, 2011
SUBMISSION CONTROL NO: 143857
© 2009, Genzyme Canada Inc.
® FLUDARA is a registered trademark exclusively licensed to Genzyme
Corporation.
_ _
_ _
_Page 2 of 49 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................8
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND
ADMINISTRATION..............................................................................11
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND
STABILITY..........................................................................................14
SPECIAL HANDLING INSTRUCTIONS
.......................................................................15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................15
PART II: SCIENTIFIC INFORMATION
................................................................................17
PHARMACEUTICAL
INFORMATIO